Degarelix: a new hormonal treatment for prostate cancer

According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales.¹ The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.